ImmunityBio Inc.’s shares have surged about 266% year‑to‑date, spurred by a $100 million financing round and global expansion plans.

The rally matters because it signals strong investor confidence in a mid‑stage biotech that is scaling beyond the U.S. market, while delivering higher product revenues. Wall Street analysts see the move as a bellwether for the sector’s ability to fund growth without diluting existing shareholders.

The stock climbed from $1.98 at the end of 2025 to $7.25 in March 2026, a rise of roughly 266% [1]. A single trading day in early April saw the price jump 15.17% to $7.67 [6], and an earlier report noted gains of more than 11% on a separate occasion [4]. These gains place ImmunityBio among the year’s top‑performing Nasdaq-listed companies.

The financing package includes a $100 million capital raise [6] and a $75 million amendment to its Revenue Interest Purchase Agreement [5]—both aimed at building manufacturing capacity in Europe and Asia. The cash infusion will underwrite new clinical sites, regulatory submissions, and marketing efforts for its pipeline.

In the first quarter of 2026, the company reported net product revenue of $44.2 million [3], reflecting stronger sales of its ANKTIVA therapy after the drug was added to the NCCN 2026 treatment guidelines. The guideline inclusion has been cited as a catalyst for the recent share price surge.

Looking ahead, ImmunityBio plans to open R&D hubs in three new regions, and to expand its commercial footprint for ANKTIVA and other late‑stage candidates. The combination of solid revenue growth, sizable financing, and endorsement by clinical guidelines positions the firm to attract further investment and potentially accelerate its path to profitability.

**What this means**: ImmunityBio’s rapid stock appreciation underscores how strategic financing and favorable clinical endorsements can transform a biotech’s growth trajectory. The company’s ability to secure large‑scale funding while delivering rising product revenues may encourage other mid‑cap biotech firms to pursue similar expansion strategies, potentially reshaping capital flows within the sector.

“ImmunityBio’s stock has climbed roughly 266% since the start of 2026.”

ImmunityBio’s rapid stock appreciation underscores how strategic financing and favorable clinical endorsements can transform a biotech’s growth trajectory, potentially reshaping capital flows within the sector.